{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.1","upperLimit":"8.9","value":"3.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"To measure changes in serum estradiol level compared to their baseline in patients with breast cancer when treated with vaginal estrogen preparation, Estring","dispersionType":"Full Range","groups":[{"description":"ESTRING® (estradiol vaginal ring) is a slightly opaque ring with a whitish core containing a drug reservoir of 2 mg estradiol. Estradiol, silicone polymers and barium sulfate are combined to form the ring. When placed in the vagina, ESTRING releases estradiol, approximately 7.5 mcg per 24 hours, in a consistent stable manner over 90 days.","id":"OG000","title":"Estring Group"}],"paramType":"MEDIAN","populationDescription":"Eligible patients were 18 years or older, diagnosed with HR-positive breast cancer defined as \\> 1% of tumor cells expressing estrogen or progesterone receptors, attained menopause as defined by the World Health Organization, and on adjuvant hormonal therapy with an aromatase inhibitor- anastrozole, letrozole, or exemestane. Patients with metastatic disease were excluded.","reportingStatus":"POSTED","timeFrame":"Baseline, 16 weeks","title":"Changes in Serum Estradiol","type":"PRIMARY","unitOfMeasure":"pg/mL"}